Process for preparing relugolix and intermediates thereof
Patent Information
- Application Number
- TW112116227
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-05-05
- Filing Date
- 2023-05-02
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2043-05-01
AI Technical Summary
Existing methods for preparing regagliflozin are inefficient and require improvements to enhance yield and efficiency.
A novel method involving intermediates (M7) and (M8) using carbonylating agents like carbonyldiimidazole (CDI) or disuccinimide carbonate to convert intermediates into regagliflozin, with specific solvents and conditions to optimize the synthesis process.
The method achieves high yields of regagliflozin, with isolated yields of at least 85-90% in some embodiments, improving the efficiency and effectiveness of the synthesis process.
Smart Images

Figure TWG2TB001920175_001 
Figure TWG2TB001920175_002 
Figure TWG2TB001920175_003
Abstract
Description
[Technical Field]
[0001] None [Previous Technology]
[0002] Regagliptin (trade name Orgovyx) is a gonadotropin-releasing hormone antagonist (GnRH receptor antagonist) drug used to treat prostate cancer in men and uterine fibroids in women.
[0003] Regaleculus is represented by formula (I): (I) represents.
[0004] The chemical name of Regagliquid is "1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-yl)-2,4-dioxy-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea" or "N-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-yl)-2,4-dioxythieno[2,3-d]pyrimidin-6-yl]phenyl]-N′-methoxyurea". The molecular formula of Regagliquid is C 29H 27F 2N 7O 5S and the molecular weight is 623.63 Da.
[0005] US Patent No. 7,300,935 discloses the preparation of regorax, as shown in Figure 1. Compound (5) of Figure 1 was prepared in four (4) steps according to Reference Example 17 of WO 2000 / 056739 as follows: i) Compound (1) was constructed from nitrophenylacetone via Gewald aminothiophene synthesis; ii) Compound (2) was formed from carbamate using ethyl chloroformate; iii) Compound (3) was produced by alkylation with 2,6-difluorobenzyl chloride; iv) Compound (4) was produced by selective bromination of compound (3) at the 4-methyl group using NBS / AIBN; and v) Compound (5) was formed by N-alkylation with (2-methoxyethyl)methylamine. Accordingly, as shown in Figure 1, regorax is prepared from compound (5) as follows: vi) compound (5) is reduced by hydrogenation with Pd / C to provide compound (6); vii) the NH2 group generated in compound (6) is condensed with methoxyamine using CDI as a coupling agent to produce the amine methoxyamine species of compound (7); viiii) compound (7) is hydrolyzed with KOH to form compound (8); ix) the bicyclic skeleton of compound (10) is formed by coupling compound (8) with 3-amino-6-methoxymethoxyamine, followed by cyclization with NaOMe by compound (9); and ix) finally, compound 10 is converted to regorax by using 1-chloroethyl chloroformate and dimethylamine. See U.S. Patent No. 7,300,935, Reference Examples 5 to 7, Example 57, and Reference Example 55.
[0006] U.S. Patent No. 9,758,528 discloses another synthetic route for preparing regorafenib and its intermediates, as shown in Figure 2. It involves the direct introduction of dimethylamine instead of (2-methoxyethyl)methylamine to generate compound (5'), followed by hydrolysis to give compound (6'). Compound (6') is coupled with a methylamine of 3-amino-6-methoxyethylamine to form compound (7'), which is then cyclized with NaOMe to give compound (8'). Compound 8' is reduced by hydrogenation with Pd / C to give compound (9'). The NH₂ group generated in compound (9') condenses with methoxyamine using CDI as a coupling agent to produce regorafenib.
[0007] Chinese Patent Application No. 111,333,633 discloses an alternative route for preparing regorafenib and its intermediates, as shown in Figure 3.
[0008] Chinese Patent Application No. 112,321,602 has confirmed another method for preparing regorafenib, as shown in Figure 4. The main difference between Figure 3 (i.e., the method of CN 111,333,633) and Figure 4 (i.e., the method of CN 112,321,602) lies in the connection sequence of the -NHC(O)NHOMe side chain of the thiophene moiety.
[0009] Despite the above methods, there is still a need to develop improved methods for preparing regorafenib. This invention addresses this need while providing related advantages. [Summary of the Invention]
[0010] This application claims priority to U.S. Provisional Patent Application No. 63 / 338,641, filed May 5, 2022, which is incorporated herein in its entirety for all purposes.
[0011] In the first state, the present invention provides a method for preparing regorax or its salt via intermediates (M7) and (M8), wherein the regorax is represented by formula (I): (I), . This method includes: a) combining a compound of formula (M7), or a salt thereof, with a carbonylating agent in a solvent to form a compound of formula (M8), or a salt thereof; and b) converting the compound of formula (M8) or its salt to a regliflozin of formula (I), or a salt thereof, wherein the carbonylating agent is carbonyl diimidazole (CDI) or disuccinimidyl carbonate; and X is imidazolyl or O-succinimidyl, or the carbonylating agent is a chloroformate selected from the group consisting of CH3OC(O)Cl, CH3CH2OC(O)Cl, phenyl-OC(O)Cl, or 4-nitrophenyl-OC(O)Cl; and X is OCH3, OCH2CH3, O-phenyl, or O-4-nitrophenyl.
[0012] In the second embodiment, the present invention provides a method for preparing regorax or a salt thereof from an intermediate (M8), wherein the regorax is represented by formula (I). The method comprises: b) combining a compound of formula (M8), or a salt thereof, with a methoxyamine or a salt thereof to provide regorax or a salt thereof of formula (I), wherein X is imidazolyl, O-succinimidyl, OCH3, OCH2CH3, O-phenyl, or O-4-nitrophenyl.
[0013] In the third state, the present invention provides a method for preparing regorax or a salt thereof via intermediates (M5) to (M8), wherein the regorax is represented by formula (I). This method includes: vi) combining a compound of formula (M5), or a salt thereof, with 6-methoxy-3-amine to form a compound of formula (M6), or a salt thereof; vii) hydrogenating the compound of formula (M6) or the salt thereof with a hydrogen source to provide a compound of formula (M7), or a salt thereof; a) combining the compound of formula (M7) or the salt thereof with a carbonylating agent in a solvent to form a compound of formula (M8), or a salt thereof; and b) converting the compound of formula (M8) or the salt thereof into a regliclazide of formula (I), or a salt thereof, wherein the carbonylating agent is carbonyl diimidazole (CDI) or disuccinimidyl carbonate; and X is an imidazolium group or an O-succinimidyl group, or the carbonylating agent is selected from CH3OC(O)Cl, CH3CH Chloroformates comprising the group consisting of 2OC(O)Cl, phenyl-OC(O)Cl, or 4-nitrophenyl-OC(O)Cl; wherein X is OCH 3, OCH 2CH 3, O-phenyl, or O-4-nitrophenyl.
[0014] In the fourth state, the present invention provides a compound selected from the group consisting of (M1), (M2), (M3), (M4), (M5), (M6), (M7), (M8), and (M8-1), or salts thereof, wherein in formula (M8), X is imidazolyl, O-succinimino, OCH3, OCH2CH3, O-phenyl, or O-4-nitrophenyl.
[0015] In the fifth state, the present invention provides a compound selected from the group consisting of (M1'), (M2'), (M3'), and (M4'), and their salts, wherein: R is a C1-4 alkyl, O-NR1R2, or ON=CR3R4; R1 and R2 are independently hydrogen, tert-butyloxycarbonyl (Boc), C1-4 alkyl, or phenyl; and R3 and R4 are independently hydrogen, C1-4 alkyl, or phenyl.
Implementation Method
[0024] I. Summary
[0025] This invention provides an improved method for preparing regorax and its intermediates. Regorax is prepared according to synthetic routes 1 to 4 of Figures 5 to 8, via intermediates (M5) to (M8), particularly intermediates (M7) and (M8). Accordingly, intermediate (M7) is reacted with a carbonylating agent (e.g., CDI) to form intermediate (M8), such as intermediate (M8-1). Regorax is provided after intermediate (M8) (e.g., intermediate (M8-1)) is reacted with methoxyamine hydrochloride or a methoxyamine free base. This invention also provides three other routes for the preparation of regorax and its intermediates (synthetic routes-2,-3, and-4), wherein the starting material ethyl 2-amino-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate (SM1) is protected by coupling with an acetyl chloride (e.g., acetyl chloride), a hydroxylamine (e.g., N-Boc-N-methylhydroxylamine), or an oxime (e.g., diphenyl ketone oxime). Accordingly, as shown in Figures 6 to 8, regorax is prepared via intermediates (M5) to (M8), which originate from intermediates (i.e., M1'-1 to M'4-1, M1'-2 to M4'-2, or M1'-3 to M4'-3). II. Definitions
[0026] Unless otherwise specified, all substituents (represented by) in all formulas of this invention (e.g., the claims, specific embodiments, and chemical formulas in Figures 1 to 8) refer to methyl groups.
[0027] "Salt" means an acid salt or alkali salt of the compound used in the methods of the present invention. Salts used in the present invention include (but are not limited to) phosphates, sulfates, chlorides, bromides, carbonates, nitrates, acetates, methanesulfonates, sodium salts, potassium salts, and calcium salts. Illustrative examples of pharmaceutically acceptable salts are mineral salts (hydrochlorides, hydrobroms, phosphates, and the like), organic acid salts (acetates, propionates, glutamates, citrates, and the like), quaternary ammonium salts (methyl iodide, ethyl iodide, and the like), and alkali metal or alkaline earth metal salts (sodium salts, potassium salts, calcium salts, and the like). It should be understood that pharmaceutically acceptable salts are non-toxic. Additional information on applicable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th edition, Mack Publishing Company, Easton, Pa., 1985, which is incorporated herein by reference.
[0028] "Base" refers to a functional group that deprotonates water to produce hydroxide ions. Bases used in this invention include organic and inorganic bases. Exemplary organic bases include tertiary amines and basic alkoxides, as defined herein. Exemplary inorganic bases include basic bicarbonates, basic carbonates, and basic hydroxides, as defined herein.
[0029] "Tertiary amine" refers to a compound having the formula N(R)3, wherein the R group can be alkyl, aryl, heteroalkyl, heteroaryl, etc., or two R groups together form an N-linked heterocyclic alkyl group. The R groups can be the same or different. Non-limiting examples of tertiary amines include triethylamine, tri-n-butylamine, N,N-diisopropylethylamine, N-methylpyrrolidone, N-methyl sulfophylline, dimethylaniline, diethylaniline, 1,8-bis(dimethylamino)naphthalene, sine, and 1,4-diazabicyclo[2.2.2]octane (DABCO).
[0030] In this document, "amidine compounds" refers to a class of chemical compounds, including (but not limited to) 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and 1,5-diazabicyclo[4.3.0]non-5-ene (DBN).
[0031] "Alkaline bicarbonate" refers to a class of chemical compounds composed of an alkali metal cation and a bicarbonate anion (HCO3-). The alkaline carbonates used in this invention include lithium bicarbonate (LiHCO3), sodium bicarbonate (NaHCO3), potassium bicarbonate (KHCO3), and cesium bicarbonate (CsHCO3).
[0032] "Alkali carbonate" refers to a class of chemical compounds composed of alkali metal cations and carbonate anions (CO3 2-). The alkali carbonates used in this invention include lithium carbonate (Li2CO3), sodium carbonate (Na2CO3), potassium carbonate (K2CO3), and cesium carbonate (Cs2CO3).
[0033] "Strong base" includes alkane oxides as defined herein.
[0034] "Alkali hydroxide" refers to a class of chemical compounds composed of alkali metal cations and hydroxide anions (OH-). The alkali hydroxides used in this invention include lithium hydroxide (LiOH), sodium hydroxide (NaOH), potassium hydroxide (KOH), cesium hydroxide (CsOH), and calcium hydroxide (Ca(OH)2).
[0035] "Alkyl alkoxide" refers to a class of chemical compounds composed of an alkali metal cation and an alkoxide anion (RO-), wherein R is a C1-4 alkyl group. Alkyl alkoxides used in this invention include (but are not limited to) sodium isopropoxide, sodium methoxide, sodium tributoxide, potassium tributoxide, and potassium isopropoxide.
[0036] "Combination" means the process of combining at least two different species together so that they are equally reactive. However, it should be understood that the resulting reaction product may be produced directly from the reaction between the added reagents, or from an intermediate of one or more added reagents, which may be generated in the reaction mixture.
[0037] "Solvent" means a substance capable of dissolving a solute, such as a liquid. Solvents can be polar or nonpolar, protic or aprotic. Polar solvents typically have a dielectric constant greater than about 5 or a dipole moment greater than about 1.0, while nonpolar solvents have a dielectric constant less than about 5 or a dipole moment less than about 1.0. Protic solvents are characterized by the presence of protons that can be removed, such as hydroxyl or carboxyl groups. Aprotic solvents lack such groups. Representative polar protic solvents include alcohols (methanol, ethanol, propanol, isopropanol, etc.), acids (formic acid, acetic acid, etc.), and water. Representative polar aprotic solvents include dichloromethane, chloroform, tetrahydrofuran, diethyl ether, acetone, ethyl acetate, dimethylformamide, dimethylacetamide, acetonitrile, and dimethyl sulfoxide. Representative nonpolar solvents include alkanes (pentane, hexane, etc.), cycloalkanes (cyclopentane, cyclohexane, etc.), benzene, toluene, diethyl ether, and 1,4-dialkylene. Other solvents may be used in this invention.
[0038] "Carbonylating agent" means a reagent that can add a carbonyl group (-C(O)-) to a compound. Representative carbonylating agents include (but are not limited to) phosgene or phosgene equivalents (e.g., diphosgene, triphosgene, carbonyl diimidazole (CDI), and disuccinimidyl carbonate), or chloroformates (e.g., CH3OC(O)Cl, CH3CH2OC(O)Cl, phenyl-OC(O)Cl, 4-nitrophenyl-OC(O)Cl, or succinimidyl chloroformate).
[0039] "Trifluoroacetylated agent" refers to a reagent that can add a trifluoroacetyl group (-C(O)CF3) to a compound. Representative trifluoroacetylated agents include (but are not limited to) trifluoroacetic anhydride (TFAA) and trifluoroacetyl chloride.
[0040] "Brominizing agent" refers to a reagent that can add a bromine group (-Br) to a compound. Representative brominating agents include (but are not limited to) bromine, N-bromosuccinimide, triphenylphosphine dibromide, tetrabutylammonium tribromide, trimethylphenylammonium tribromide, N-bromoacetamide, pyridine tribromide, dibromodimethylhydantoin, tribromoisocyanuric acid, N-bromosaccharin, and 1,2-dibromo-1,1,2,2-tetrachloroethane.
[0041] "Approximately" means a range of values including the specified value, wherein a person skilled in the art would consider reasonably similar to the specified value. In some embodiments, the term "approximately" means within the standard deviation using measurements generally acceptable in the art. In some embodiments, approximately means a range extending to + / - 10% of the specified value. In some embodiments, approximately means the specified value. III. Process
[0042] In the first state, the present invention provides a method for preparing regorax via intermediates (M7) and (M8), wherein the regorax is represented by formula (I): (I), or a salt thereof. This method includes: a) combining a compound of formula (M7), or a salt thereof, with a carbonylating agent in a solvent to form a compound of formula (M8), or a salt thereof; and b) converting the compound of formula (M8) or its salt to a regliclazide of formula (I) or a salt thereof, wherein the carbonylating agent is carbonyl diimidazole (CDI) or disuccinimidyl carbonate; and X is an imidazolyl or O-succinimidyl group, or the carbonylating agent is a chloroformate selected from the group consisting of CH3OC(O)Cl, CH3CH2OC(O)Cl, phenyl-OC(O)Cl, or 4-nitrophenyl-OC(O)Cl; and X is OCH3, OCH2CH3, O-phenyl, or O-4-nitrophenyl.
[0043] In the second state, the present invention provides a method for preparing regoraxol from an intermediate (M8), the regoraxol being represented by formula (I) or a salt thereof. The method comprises: b) combining a compound of formula (M8), (M8), or a salt thereof with a methoxyamine or a salt thereof to provide regoraxol of formula (I) or a salt thereof, wherein X is imidazolyl, O-succinimidyl, OCH3, OCH2CH3, O-phenyl, or O-4-nitrophenyl.
[0044] In some specific embodiments, step a) further includes a base, which is a tertiary amine and / or an amidine compound. In some specific embodiments, the tertiary amine is triethylamine, tri-n-butylamine, N,N-diisopropylethylamine, N-methylpyrrolidone, N-methylpiperidine, dimethylaniline, diethylaniline, 1,8-bis(dimethylamino)naphthalene, sine, 1,4-diazabicyclo[2.2.2]octane (DABCO), or a mixture thereof. In some specific embodiments, the amidine compound is 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), or a mixture thereof. In some specific embodiments, step a) further includes 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
[0045] Referring to step a), in some specific embodiments, the carbonylating agent is carbonyl diimidazole (CDI) or disuccinimidyl carbonate. In some specific embodiments, the carbonylating agent is carbonyl diimidazole (CDI). In some specific embodiments, the carbonylating agent is disuccinimidyl carbonate. In some specific embodiments, the carbonylating agent is a chloroformate selected from the group consisting of CH3OC(O)Cl, CH3CH2OC(O)Cl, phenyl-OC(O)Cl, or 4-nitrophenyl-OC(O)Cl.
[0046] In some specific embodiments, the carbonylating agent is carbonyl diimidazole (CDI) or disuccinimidyl carbonate; and X in formula (M8) is either imidazole group or O-succinimidyl group. In some specific embodiments, the carbonylating agent is carbonyl diimidazole (CDI); and X in formula (M8) is imidazole group. In some specific embodiments, the carbonylating agent is disuccinimidyl carbonate; and X in formula (M8) is O-succinimidyl group. In some specific embodiments, the carbonylating agent is a chloroformate selected from the group consisting of CH3OC(O)Cl, CH3CH2OC(O)Cl, phenyl-OC(O)Cl, or 4-nitrophenyl-OC(O)Cl; and X in formula (M8) is OCH3, OCH2CH3, O-phenyl, or O-4-nitrophenyl.
[0047] In some specific embodiments, X in formula (M8) is an imidazole group; and the compound of formula (M8) is a compound represented by formula (M8-1): (M8-1), or a salt thereof.
[0048] In some specific embodiments, the carbonylating agent is carbonyl diimidazole (CDI); X in formula (M8) is an imidazole group; and the compound of formula (M8) is a compound or a salt of formula (M8-1).
[0049] Referring to step a), in some specific embodiments, the solvent is an aprotic solvent. Suitable aprotic solvents include tetrahydrofuran (THF), 2-methyltetrahydrofuran (2-MeTHF), ethyl acetate (EtOAc), dimethylformamide (DMF), dichloromethane (DCM), toluene, dimethylacetamide (DMAc), isopropyl acetate (IPAc), acetonitrile, or mixtures thereof. In some specific embodiments, the solvent is an aprotic solvent selected from the group consisting of tetrahydrofuran (THF), 2-methyltetrahydrofuran (2-MeTHF), ethyl acetate (EtOAc), dimethylformamide (DMF), dichloromethane (DCM), toluene, dimethylacetamide (DMAc), isopropyl acetate (IPAc), acetonitrile, or mixtures thereof. In some specific embodiments, the solvent is THF.
[0050] Referring to step b), in some specific embodiments, step b) is performed without separating the (M8) compound or its salt. In some specific embodiments, the (M8) compound or its salt is prepared in situ. In some specific embodiments, step b) is performed without separating the (M8-1) compound or its salt. In some specific embodiments, the (M8-1) compound or its salt is prepared in situ.
[0051] Generally, step b) can be carried out by combining a compound of formula (M8) or a salt thereof (e.g., formed in step a) with a methoxyamine or a salt thereof in any order. In some specific embodiments, regorax of formula (I) or a salt thereof is formed by: 1) adding a compound of formula (M8) or a salt thereof (e.g., formed in step a) to a methoxyamine or a salt thereof; or 2) adding a methoxyamine or a salt thereof to a compound of formula (M8) or a salt thereof (e.g., formed in step a).
[0052] In some embodiments, the mixture of step a) (including the compound of formula (M8) or a salt thereof) is added to a methoxyamine or a salt thereof to form regoraxol of formula (I) or a salt thereof. In some embodiments, the mixture of step a) (including the compound of formula (M8) or a salt thereof) is added to a solution of a methoxyamine or a salt thereof to form regoraxol of formula (I) or a salt thereof. In some embodiments, the solution of the methoxyamine or a salt thereof is formed in the same solvent as in step a). In some embodiments, the mixture of step a) includes a compound of formula (M8-1) or a salt thereof and THF; and the solution of the methoxyamine or a salt thereof includes methoxyamine and THF.
[0053] In some specific embodiments, methoxyamine or a salt thereof is added to the mixture of step a) (including the compound of formula (M8) or a salt thereof) to form regorax of formula (I) or a salt thereof. In some specific embodiments, methoxyamine hydrochloride is added to the mixture of step a) (including the compound of formula (M8-1) or a salt thereof) to form regorax of formula (I) or a salt thereof.
[0054] Generally, step a) can be performed at any applicable temperature. In some specific embodiments, step a) is performed at a temperature between 20°C and 50°C. In some specific embodiments, step a) is performed at room temperature.
[0055] Generally, step b) can be performed at any applicable temperature. In some embodiments, step b) is performed at a temperature between 20°C and 50°C. In some embodiments, step b) is performed at room temperature. In some embodiments, step b) is performed in THF at room temperature.
[0056] In some embodiments, the separation yield of regorafenib in the two steps (i.e., steps a) and b) is at least about 85% or about 90%. In some embodiments, the yield of regorafenib separated via steps a) and b) is at least about 90% (e.g., 92.9%). In some embodiments, the yield of regorafenib separated via steps a) and b) is about 92.9%.
[0057] In some specific embodiments, prior to step a), the method further includes steps vi) to vii: vi) combining compound (M5) of formula (M5), or a salt thereof, with 6-methoxy-3-amine to form compound (M6) of formula (M6), or a salt thereof; vii) hydrogenating compound (M6) or salt thereof with a hydrogen source to provide compound (M7) of formula (M7), or a salt thereof.
[0058] In the third state, the present invention provides a method for preparing regorax via intermediates (M5) to (M8), wherein the regorax is represented by formula (I) or a salt thereof. This method includes: vi) combining a compound of formula (M5), or a salt thereof, with 6-methoxy-3-amine to form a compound of formula (M6), or a salt thereof; vii) hydrogenating the compound of formula (M6) or its salt with a hydrogen source to provide a compound of formula (M7), or a salt thereof; a) combining the compound of formula (M7) or its salt with a carbonylating agent in a solvent to form a compound of formula (M8), or a salt thereof; and b) converting the compound of formula (M8) or its salt to a regliclazide of formula (I) or a salt thereof, wherein the carbonylating agent is carbonyl diimidazole (CDI) or disuccinimidyl carbonate; and X is an imidazolium group or an O-succinimidyl group, or the carbonylating agent is selected from CH3OC(O)Cl, CH3CH Chloroformates comprising the group consisting of 2OC(O)Cl, phenyl-OC(O)Cl, or 4-nitrophenyl-OC(O)Cl; wherein X is OCH 3, OCH 2CH 3, O-phenyl, or O-4-nitrophenyl.
[0059] Referring to step vi), in some specific embodiments, step vi) is carried out in an aprotic solvent with 6-methoxy-3-amine and a amide coupling agent. In some specific embodiments, step vi) is carried out in DCM with 6-methoxy-3-amine and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI). In some specific embodiments, step vi) is carried out in DCM at room temperature. In some specific embodiments, the separation yield of compound (M6) is >90% (e.g., 91%).
[0060] Referring to step vii), in some embodiments, the hydrogen source is hydrogen gas. In some embodiments, step vii) is carried out in an alcohol (e.g., MeOH) with hydrogen gas containing more than 10% Pd / C. In some embodiments, step vii) is carried out in methanol (MeOH) with hydrogen gas containing more than 10% Pd / C. In some embodiments, step vii) is carried out in methanol (MeOH) in the presence of an acid (e.g., 32% HCl) with hydrogen gas containing more than 10% Pd / C. In some embodiments, step vii) is carried out in methanol (MeOH) in the presence of HCl (e.g., 32% HCl) with hydrogen gas containing more than 10% Pd / C. In some embodiments, step vii) is carried out at room temperature. In some embodiments, the separation yield of compound (M7) is > 95% (e.g., 96%).
[0061] Steps a) and b) are as described herein. IIIA. Synthetic Pathway-1
[0062] Regaglik of formula (I) or its salt can be prepared by the following nine (9) steps: Steps i) to v) via intermediates (M1) to (M4) to provide intermediate (M5); Steps vi) and vii) via intermediates (M5) and (M6) to provide intermediate (M7); and finally, steps a) and b) via intermediates (M7) and (M8) to provide regaglik of formula (I) or its salt.
[0063] Figure 5 shows a representative synthesis flowchart of this approach.
[0064] In some specific embodiments, prior to step a), the method further includes steps i) to vii): i) combining compound (SM1) or a salt thereof with 2,6-difluorobenzyl bromide or 2,6-difluorobenzyl chloride to form compound (M1) or a salt thereof; ii) combining compound (M1) or a salt thereof with a trifluoroacetic agent to form compound (M2) or a salt thereof; iii) brominating compound (M2) or a salt thereof with a brominating agent to form compound (M3) or a salt thereof; iv) combining compound (M3) or a salt thereof with dimethylamine or a salt thereof to provide compound (M4) or a salt thereof; v) hydrolyzing compound (M4) or a salt thereof with a base to provide compound (M5) or a salt thereof; vi) The compound or salt of formula (M5) is combined with 6-methoxy-3-amine to form a compound of formula (M6): (M6), or a salt thereof; and vii) the compound or salt of formula (M6) is hydrogenated with a hydrogen source to provide a compound or salt of formula (M7): (M7).
[0065] Referring to step i), in some specific embodiments, step i) is carried out in an aprotic solvent with 2,6-difluorobenzyl bromide. In some specific embodiments, step i) is carried out in dimethylacetamide (DMAc) with 2,6-difluorobenzyl bromide. In some specific embodiments, step i) is carried out at a temperature of about 80°C. In some specific embodiments, the separation yield of compound (M1) is > 90% (e.g., about 94%).
[0066] Referring to step ii), in some specific embodiments, step ii) is carried out in an aprotic solvent with a trifluoroacetic agent and a tertiary amine. In some specific embodiments, the trifluoroacetic agent is trifluoroacetic anhydride (TFAA). In some specific embodiments, step ii) is carried out in dichloromethane (DCM) with trifluoroacetic anhydride (TFAA) and triethylamine (TEA). In some specific embodiments, step ii) is carried out at a temperature of about 25°C. In some specific embodiments, the separation yield of compound (M2) is > 90% (e.g., about 95%).
[0067] Referring to step iii), in some specific embodiments, step iii) is carried out in an aprotic solvent with a brominating agent and a free radical initiator (e.g., azobisisobutyronitrile). In some specific embodiments, the brominating agent is N-bromosuccinimide. In some specific embodiments, step iii) is carried out in a mixture of ethyl acetate (EtOAc) and trifluorotoluene with N-bromosuccinimide and azobisisobutyronitrile (AIBN). In some specific embodiments, step iii) is carried out at a temperature of about 70°C. In some specific embodiments, the separation yield of compound (M3) is about 90%.
[0068] Referring to step iv), in some specific embodiments, step iv) is carried out in an aprotic solvent with dimethylamine or dimethylamine hydrochloride and a tertiary amine. In some specific embodiments, step iv) is carried out in dimethylacetamide (DMAc) with dimethylamine hydrochloride and trimethylamine. In some specific embodiments, step iv) is carried out at a temperature from about 0°C to room temperature. In some specific embodiments, the compound of formula (M4) is converted to its hydrochloride (HCl). In some specific embodiments, the separation yield of the hydrochloride of compound (M4) is > 95% (e.g., 98%).
[0069] Referring to step v), in some specific embodiments, step v) is carried out in an alcohol with an alkaline hydroxide. In some specific embodiments, the alkaline hydroxide is sodium hydroxide. In some specific embodiments, sodium hydroxide is in an aqueous solution. In some specific embodiments, step v) is carried out in ethanol (EtOH) with an aqueous solution of sodium hydroxide. In some specific embodiments, step v) is carried out at a temperature of about 70°C to about 80°C. In some specific embodiments, the separation yield of compound (M5) is > 90% (e.g., 92%).
[0070] Referring to step vi), in some specific embodiments, step vi) is carried out in an aprotic solvent with 6-methoxy-3-amine and a amide coupling agent. In some specific embodiments, step vi) is carried out in DCM with 6-methoxy-3-amine and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI). In some specific embodiments, step vi) is carried out in DCM at room temperature. In some specific embodiments, the separation yield of compound (M6) is >90% (e.g., 91%).
[0071] Referring to step vii), in some specific embodiments, the hydrogen source is hydrogen gas. In some specific embodiments, step vii) is carried out in an alcohol (e.g., MeOH) with hydrogen gas containing more than 10% Pd / C. In some specific embodiments, step vii) is carried out in methanol (MeOH) with hydrogen gas containing more than 10% Pd / C. In some specific embodiments, step vii) is carried out in methanol (MeOH) in the presence of an acid (e.g., 32% HCl) with hydrogen gas containing more than 10% Pd / C. In some specific embodiments, step vii) is carried out in methanol (MeOH) in the presence of HCl (e.g., 32% HCl) with hydrogen gas containing more than 10% Pd / C. In some specific embodiments, step vii) is carried out at room temperature. In some specific embodiments, the separation yield of compound (M7) is > 95% (e.g., 96%).
[0072] In one embodiment, the present invention provides a method for preparing a compound of formula (M1) according to step i), a compound of formula (M2) according to step ii) or step i)-ii), a compound of formula (M3) according to step iii) or step i)-iii), a compound of formula (M4) according to step iv) or step i)-iv), a compound of formula (M5) according to step v) or step i)-v), a compound of formula (M6) according to step vi) or step i)-vi), or a compound of formula (M7) according to step vii) or step i)-vii), wherein each of the above is defined and described herein.
[0073] In another embodiment, the present invention provides a method for preparing regorax or a salt thereof of formula (I) according to steps i) to vii) and steps a) and b), wherein each is defined and described herein. IIIA. Synthetic pathways-2,-3, and-4
[0074] The regorax of formula (I) or its salt can be prepared by the following nine (9) steps: Steps i-1) to v-1) via intermediates (M1') to (M4') to provide intermediate (M5); Steps vi) and vii) via intermediates (M5) and (M6) to provide intermediate (M7); and finally, steps a) and b) via intermediates (M7) and (M8) to provide the regorax of formula (I) or its salt.
[0075] Figures 6 to 8 show representative synthesis flowcharts of these pathways.
[0076] In some specific embodiments, prior to step vi), the method further includes steps i-1) to vii-1): i-1) combining compound (SM1) of formula (SM1), or a salt thereof, with compound SM2 C1-4 alkyl-C(O)Cl or a combination of a carbonylating agent and compound SM2 hydroxylamine or oxime to form compound (M1') of formula (M1'), or a salt thereof; ii-1) combining compound (M1') or a salt thereof with 2,6-difluorobenzyl bromide or 2,6-difluorobenzyl chloride to form compound (M2') of formula (M2'), or a salt thereof; iii-1) brominating compound (M2') or a salt thereof with a brominating agent to form compound (M3') of formula (M3'), or a salt thereof; iv-1) combining compound (M3') or a salt thereof with dimethylamine or a salt thereof to provide compound (M4') of formula (M4'), or a salt thereof; v-1) Hydrolyzing a compound or salt of formula (M4') with a base to provide a compound or salt of formula (M5): (M5), wherein: the hydroxylamine series is represented by HO-NR 1R 2; and the oxime series is represented by HO-N=CR 3R 4; in any of formulas M1' to M4', R is C 1-4 alkyl, O-NR 1R 2, or ON=CR 3R 4; R1 and R2 are independently hydrogen, tributyloxycarbonyl (Boc), C 1-4 alkyl, or phenyl; and R3 and R4 are independently hydrogen, C 1-4 alkyl, or phenyl.
[0077] Referring to step i-1), in some specific embodiments, compound SM2 is a C1-4 alkyl-C(O)Cl. In some specific embodiments, compound SM2 is acetyl chloride.
[0078] Referring to step i-1), in some specific embodiments, compound SM2 is a hydroxylamine or an oxime; and the carbonylating agent is carbonyl diimidazole (CDI), disuccinimide carbonate, CH3OC(O)Cl, CH3CH2OC(O)Cl, phenyl-OC(O)Cl, or 4-nitrophenyl-OC(O)Cl. In some specific embodiments, the carbonylating agent is carbonyl diimidazole (CDI) or disuccinimide carbonate. In some specific embodiments, the carbonylating agent is carbonyl diimidazole (CDI). In some specific embodiments, the hydroxylamine is N-Boc-N-methylhydroxylamine. In some specific embodiments, the oxime is diphenyl ketoxime.
[0079] Referring to step ii-1), in some specific embodiments, step ii-1) is carried out in dimethylacetamide (DMAc) with 2,6-difluorobenzyl bromide.
[0080] Referring to step iii-1), in some specific embodiments, the brominating agent is N-bromosuccinimide. In some specific embodiments, step iii-1) is carried out in a solvent including ethyl acetate (EtOAc) with N-bromosuccinimide and azobisisobutyronitrile.
[0081] Referring to step iv-1), in some specific embodiments, step iv-1) is carried out in dimethylacetamide (DMAc) with dimethylamine or dimethylamine hydrochloride and triethylamine.
[0082] Referring to step v-1), in some specific embodiments, step v-1) is carried out in ethanol (EtOH) with sodium hydroxide.
[0083] Referring to step i-1), in some specific embodiments, compound SM is C1-4 alkyl-C(O)Cl; and any of the compounds of formula (M1') to (M4') are represented by compounds of formula (M1'-1) to (M4'-1): (M1'-1), (M2'-1), (M3'-1), and (M4'-1), or salts thereof.
[0084] Referring to step i-1), in some specific embodiments, compound SM is acetyl chloride, and any of the compounds of formula (M1'-1) to (M4'-1) are represented by compounds of formula (M1'-1a) to (M4'-1a): (M1'-1a), (M2'-1a), (M3'-1a), and (M4'-1a), or salts thereof.
[0085] Referring to step i-1), in some specific embodiments, compound SM2 is a hydroxylamine or oxime; and any of the compounds of formula (M1') to (M4') are represented by compounds of formula (M1'-2) to (M4'-2) and (M1'-3) to (M4'-3): (M1'-2), (M2'-2), (M3'-2), (M4'-2), (M1'-3), (M2'-3), (M3'-3), (M4'-3), or salts thereof, wherein R1 and R2 are independently hydrogen, tert-butyloxycarbonyl (Boc), C1-4 alkyl, or phenyl; and R3 and R4 are independently hydrogen, C1-4 alkyl, or phenyl.
[0086] Referring to step i-1), in some specific embodiments, the hydroxylamine is N-Boc-N-methylhydroxylamine; and any of the compounds of formula (M1'-2) to (M4'-2) are represented by compounds of formula (M1'-2a) to (M4'-2a): (M1'-2a), (M2'-2a), (M3'-2a), and (M4'-2a), or salts thereof.
[0087] Referring to step i-1), in some specific embodiments, the oxime is a diphenyl ketone oxime; and any compound of formula (M1'-3) to (M4'-3) is represented by a compound of formula (M1'-3a) to (M4'-3a): (M1'-3a), (M2'-3a), (M3'-3a), and (M4'-3a), or a salt thereof. IV. Compounds
[0088] In the fourth state, the present invention provides a compound selected from the group consisting of (M1), (M2), (M3), (M4), (M5), (M6), (M7), (M8), and (M8-1), or salts thereof, wherein in formula (M8), X is imidazolyl, O-succinimino, OCH3, OCH2CH3, O-phenyl, or O-4-nitrophenyl.
[0089] In the fifth state, the present invention provides a compound selected from the group consisting of (M1'), (M2'), (M3'), and (M4'), and their salts, wherein: R is a C1-4 alkyl, O-NR1R2, or ON=CR3R4; R1 and R2 are independently hydrogen, tert-butyloxycarbonyl (Boc), C1-4 alkyl, or phenyl; and R3 and R4 are independently hydrogen, C1-4 alkyl, or phenyl.
[0090] In some specific embodiments, the compound is selected from the group consisting of (M1'-1a), (M2'-1a), (M3'-1a), (M4'-1a), (M1'-2a), (M2'-2a), (M3'-2a), and (M4'-2a), (M1'-3a), (M2'-3a), (M3'-3a), and (M4'-3a), or salts thereof. V. Examples Example 1: Preparation of regorax via synthetic route-1
[0091] The synthetic route for preparing regorafenib-1 is described in Figure 5.
[0092] In synthetic route-1, SM1 is alkylated with 2,6-difluorobenzyl chloride to obtain M1, followed by acetylation with TFAA to obtain M2. In the presence of AIBN (as a radical initiator), the reaction of M2 with NBS allows for selective bromination at the methyl group to generate M3. Subsequently, the bromo group in M3 is substituted with triethylamine as a base via dimethylamine hydrochloride to obtain M4. M4 is hydrolyzed with NaOH to generate M5, which is then coupled with 3-amino-6-methoxydimethylamine to obtain M6. The nitro group in M6 is hydrogenated with Pd / C to form M7. Activation of the NH2 group in M7 allows for cyclization initiated via CDI / DBU to generate M8-1. Finally, regorax can be synthesized via the reaction of M8-1 with methoxydimethylamine hydrochloride. Preparation of M1
[0093] SM1 (10.0 g), 2,6-difluorobenzyl bromide (8.12 g), and DMAc (100 mL) were added to a suitable reactor. The resulting mixture was heated to 80°C and then stirred overnight. After completion, the reaction was cooled to room temperature, and then an aqueous solution of NaHCO3 (200 mL) was added. The resulting slurry was stirred at room temperature for 1 hour. After filtration, the wet filter cake was washed with H2O and then dried under vacuum at 60°C to give M1 (13.3 g, 94% yield). Preparation of M2
[0094] M1 (5.0 g), DCM (50 mL), and triethylamine (4.5 mL) were added to a suitable reactor. The mixture was cooled to 0 to 10 °C. TFAA (6.80 g) was slowly added. The resulting mixture was brought to room temperature and then stirred for 12 hours. After this was completed, an aqueous solution of NaHCO3 (100 mL) was added to quench the reaction. The solution was stirred at room temperature for 1 hour. After phase separation, the organic layer was washed three times with H2O (50 mL) and then the solvent was exchanged with n-heptane to three volumes. The resulting slurry was filtered through a Büchner funnel. The wet filter cake was washed with n-heptane (15 mL) and then dried under vacuum at 50 °C to give M2 (5.83 g, 95% yield). Preparation of M3
[0095] M2 (10.0 g), EtOAc (40 mL), and trifluorotoluene (40 mL) were added to a suitable reactor. N-bromosuccinimide (4.21 g) and AIBN (0.31 g) were added. The reaction mixture was heated to 70 °C and then stirred for 4 hours. After completion, the reaction was cooled to room temperature and washed twice with H2O (40 mL). The organic layer was concentrated to 4 volumes by solvent exchange with EtOH. n-Heptane (40 mL) was slowly added. The resulting suspension was cooled to 0 °C and then stirred for 1 hour. After filtration, the wet filter cake was washed with EtOH / n-heptane (20 mL, v / v = 1 / 2) and then dried under vacuum at 45 °C to give M3 (10.3 g, 90% yield). Preparation of M4
[0096] M3 (12.0 g), dimethylamine hydrochloride (2.45 g), and DMAc (72 mL) were added to a suitable reactor. The mixture was cooled to 0 to 10 °C. Triethylamine (5.28 g) was added dropwise. The resulting mixture was brought to room temperature and then stirred for 12 hours. After this, IPAc (96 mL) and H2O (48 mL) were added. After phase separation, the organic layer was washed sequentially with H2O (48 mL), NaHCO3 aqueous solution (48 mL), and H2O (48 mL). The organic layer was concentrated to 3 volumes by exchanging the solvent with toluene. IPA (12 mL) containing 32% HCl (2.26 g) was added. The resulting mixture was concentrated to 3 volumes by exchanging the solvent with toluene. n-Heptane (36 mL) was added. The slurry was cooled to 0 to 10 °C and then stirred for 1 hour. After filtration, the wet filter cake was washed with toluene / n-heptane (30 mL, v / v = 1 / 1) and then dried under vacuum at 45 °C to give M4 hydrochloride (11.85 g, 98% yield). Preparation of M5
[0097] M4 hydrochloride (2.0 g) and EtOH (20 mL) were added to a suitable reactor. The mixture was heated to 55 to 60 °C, and then 10% NaOH (5.9 mL) was added. The mixture was heated to 70 to 80 °C and then stirred overnight. After this, the solution was cooled to room temperature, and then H2O (36 mL) was added. The solution was neutralized to pH 5 to 6 with 1N HCl. The resulting suspension was cooled to 0 to 10 °C and then stirred for 1 hour. After filtration, the wet filter cake was washed with H2O (10 mL) and then dried under vacuum at 60 °C to give M5 (1.36 g, 92% yield). Preparation of M6
[0098] M5 (5.00 g), 3-amino-6-methoxydimethacin (1.70 g), EDCI hydrochloride (4.29 g), and DCM (50 mL) were added to a suitable reactor. The mixture was stirred overnight at room temperature. After this, H2O (100 mL) was added. The mixture was stirred at room temperature for 1 hour. After phase separation, the organic layer was washed twice with H2O (15 mL) and then concentrated to 3 volumes by solvent exchange with IPA. H2O (30 mL) was added to the resulting suspension. The mixture was stirred at room temperature for 1 hour. After filtration, the wet filter cake was washed with IPA / H2O (15 mL, v / v = 1 / 2) and then dried under vacuum at 50 °C to give M6 (5.64 g, 91% yield). Preparation of M7
[0099] M6 (1.29 g) and MeOH (15 mL) were added to a suitable reactor. 32% HCl (0.64 mL) was added, followed by Pd / C (10 wt%). The mixture was stirred overnight at 0.1 to 0.2 MPa hydrogen pressure at room temperature. After completion, the mixture was filtered through a Buchner funnel containing a diatomaceous earth pad. The diatomaceous earth pad was washed with MeOH (4 mL). The combined filtrate was concentrated to 5 volumes, followed by the addition of an aqueous solution of NaHCO3 (8 mL). H2O (6 mL) was added to the resulting suspension. The mixture was stirred at room temperature for 1 hour. After filtration, the wet filter cake was washed with MeOH / H2O (4 mL, v / v = 1 / 3) and then dried under vacuum at 55 °C to give M7 (1.17 g, 96% yield). Preparation of Regorafenib
[0100] M7 (27.0 g), CDI (27.5 g), and THF (216 mL) were added to a suitable reactor, followed by DBU (9.47 g). The mixture was stirred at room temperature for 3 hours. After completion, methoxyamine hydrochloride (21.6 g) and THF (162 mL) were added to another reactor, followed by TEA (20.9 g). The above M8-1 solution was slowly added to the reactor containing methoxyamine. THF (54 mL) was added for rinsing. The mixture was stirred at room temperature for 2 hours. After completion, the reaction solution was concentrated to 5 volumes by solvent exchange with EtOAc. EtOAc (270 mL) was added, followed by 5% NaHCO3 (405 mL). The resulting mixture was stirred at room temperature for 30 minutes. The resulting suspension was filtered through a Buchner funnel, retaining the solids. The organic layer was washed three times with H2O (135 mL). The organic layer was combined with the solid described above and then concentrated to 5 volumes by solvent exchange with MeOH. The suspension was heated to reflux and then stirred for 1 hour. The suspension was cooled to room temperature and then stirred for 2 hours. After filtration, the wet filter cake was washed with MeOH / H₂O (81 mL, v / v = 2 / 1) and then dried under vacuum at 45°C to give regorafenib (29.8 g, 92.9% yield). Example 2: Preparation of regorafenib via synthetic route-2
[0101] The synthetic route for preparing regorafenib-2 is described in Figure 6.
[0102] In synthetic route-2, SM1 is acetochloroacetylated to generate M1'-1, followed by N-alkylation with 2,6-difluorobenzyl bromide to give M2'-1. In the presence of AIBN (as a radical initiator), the reaction of M2'-1 with NBS can be selectively brominated at the methyl group to generate M3'-1. Subsequently, the bromo group in M3'-1 can be substituted with dimethylamine to give M4'-1. Simultaneously, M5 can be obtained by hydrolysis of M4'-1. Regagliquid can be obtained from M5 as described in synthetic route-1. Example 3: Preparation of Regagliquid via synthetic route-3 or route-4
[0103] In synthetic pathway-3 or pathway-4, SM1 is coupled with a hydroxylamine (such as N-Boc-N-methylhydroxylamine) or an oxime (such as diphenyl ketone oxime) using CDI to generate M1'-2 or M1'-3, followed by N-alkylation with 2,6-difluorobenzyl chloride to give M2'-2 or M2'-3. In the presence of AIBN (as a radical initiator), the reaction of M2'-2 or M2'-3 with NBS can be selectively brominated at the methyl group to generate M3'-2 or M3'-3. Subsequently, the bromo group in M3'-2 or M3'-3 can be substituted with dimethylamine to give M4'-2 or M4'-3. Simultaneously, M5 can be obtained by hydrolysis of M4'-2 or M4'-3. Regagliq can be obtained from M5 as described in synthetic pathway-1.
[0104] Although the invention has been described in detail by way of illustration and examples for clarity of understanding, those skilled in the art will understand that certain changes and modifications may be made within the scope of the appended claims. Furthermore, each reference provided herein is incorporated by reference in its entirety to the same extent as each reference is individually incorporated by reference. In the event of any conflict between this application and the references provided herein, this application shall prevail. [Simplified Explanation of the Diagram]
[0016] Figure 1 shows the preparation of regorax as disclosed in U.S. Patent No. 7,300,935.
[0017] Figure 2 shows the preparation of regorax as disclosed in U.S. Patent No. 9,758,528.
[0018] Figure 3 shows the preparation of regorax as disclosed in Chinese Patent Application No. 111,333,633.
[0019] Figure 4 shows the preparation of regorafenib as disclosed in Chinese Patent Application No. 112,321,602.
[0020] Figure 5 shows the preparation of regorax via synthetic route-1.
[0021] Figure 6 shows the preparation of regorax via synthetic pathway-2.
[0022] Figure 7 shows the preparation of regorax via synthetic pathway-3.
[0023] Figure 8 shows the preparation of regorax via synthetic pathway-4.
Claims
1. A method for preparing regorafenib, the regorafenib being represented by formula (I): (I), or a salt thereof, comprising: a) combining a compound of formula (M7): (M7), or a salt thereof with a carbonylating agent in a solvent to form a compound of formula (M8): (M8), or a salt thereof; and b) converting the compound of formula (M8) or the salt thereof into regorafenib of formula (I), or a salt thereof, wherein the carbonylating agent is carbonyl diimidazole (CDI) or disuccinimidyl carbonate; and X is imidazolyl or O-succinimidyl, or the carbonylating agent is a chloroformate selected from the group consisting of CH3OC(O)Cl, CH3CH2OC(O)Cl, phenyl-OC(O)Cl, or 4-nitrophenyl-OC(O)Cl; and X is OCH3, OCH2CH3, O-phenyl, or O-4-nitrophenyl.
2. A method for preparing regorafenib, the regorafenib being represented by formula (I): (I), or a salt thereof, comprising: b) combining a compound of formula (M8): (M8), or a salt thereof with a methoxyamine or a salt thereof to provide regorafenib of formula (I) or a salt thereof, wherein X is imidazolyl, O-succinimidyl, OCH3, OCH2CH3, O-phenyl, or O-4-nitrophenyl.
3. The method of claim 1, wherein the carbonylating agent is carbonyl diimidazole (CDI) and X is an imidazole group; or the carbonylating agent is disuccinimidyl carbonate and X is an O-succinimidyl group.
4. The method of claim 3, wherein the carbonylating agent is carbonyl diimidazole (CDI) and X is an imidazole group.
5. The method of any one of claims 1 to 4, wherein X is an imidazole group; and the compound of formula (M8) is a compound represented by formula (M8-1): (M8-1), or a salt thereof.
6. The method of claim 1, wherein the solvent is an aprotic solvent selected from the group consisting of tetrahydrofuran (THF), 2-methyltetrahydrofuran (2-MeTHF), ethyl acetate (EtOAc), dimethylformamide (DMF), dichloromethane (DCM), toluene, dimethylacetamide (DMAc), isopropyl acetate (IPAc), acetonitrile, or mixtures thereof.
7. The method of claim 6, wherein the solvent is THF.
8. The method of claim 1, wherein step a) further comprises a base selected from the group consisting of triethylamine, tri-n-butylamine, N,N-diisopropylethylamine, N-methylpyrrolidone, N-methylpyrrolidone, dimethylaniline, diethylaniline, 1,8-bis(dimethylamino)naphthalene, aziridine, 1,4-diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), and mixtures thereof.
9. The method of claim 8, wherein step a) further comprises 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
10. The method of claim 1, prior to step a), further comprises steps i) to vii): i) combining a compound of formula (SM1): (SM1), or a salt thereof, with 2,6-difluorobenzyl bromide or 2,6-difluorobenzyl chloride to form a compound of formula (M1): (M1), or a salt thereof; ii) combining a compound of formula (M1) or a salt thereof with a trifluoroacetylating agent to form a compound of formula (M2): (M2), or a salt thereof; iii) brominating a compound of formula (M2) or a salt thereof with a brominating agent to form a compound of formula (M3): (M3), or a salt thereof; iv) combining a compound of formula (M3) or a salt thereof with dimethylamine or a salt thereof to provide a compound of formula (M4): (M4), or a salt thereof; v) hydrolyzing a compound of formula (M4) or a salt thereof with a base to provide a compound of formula (M5): (M5), or a salt thereof; vi) The compound or salt of formula (M5) is combined with 6-methoxy-3-amine to form a compound of formula (M6): (M6), or a salt thereof; and vii) the compound or salt of formula (M6) is hydrogenated with a hydrogen source to provide a compound or salt of formula (M7): (M7).
11. As in request item 10, wherein: In step ii), the trifluoroacetic agent is trifluoroacetic anhydride (TFAA); in step iii), the brominating agent is N-bromosuccinimide; in step v), the base is sodium hydroxide; and in step vii), the hydrogen source is hydrogen gas.
12. As in request item 10, wherein: Step i) is carried out in dimethylacetamide (DMAc) with 2,6-difluorobenzyl bromide or 2,6-difluorobenzyl chloride; Step ii) is carried out in dichloromethane (DCM) with trifluoroacetic anhydride (TFAA) and triethylamine (TEA); Step iii) is carried out in a mixture of ethyl acetate (EtOAc) and trifluorotoluene with N-bromosuccinimide and azobisisobutyronitrile; Step iv) is carried out in dimethylacetamide (DMAc) with dimethylamine hydrochloride and trimethylamine; optionally, in isopropanol, the hydrochloride of compound (M4) is converted by adding hydrochloride; Step v) is carried out in ethanol (EtOH) with sodium hydroxide; Step vi) is carried out in dichloromethane (DCM) with 6-methoxy-3-amine and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) hydrochloride; and step vii) is carried out in methanol (MeOH) with hydrogen containing more than 10% Pd / C.
13. A compound selected from the group consisting of (M1), (M2), (M3), (M4), (M5), (M8), and (M8-1), or salts thereof, wherein, In formula (M8), X is imidazolyl, O-succinimino, OCH3, OCH2CH3, O-phenyl, or O-4-nitrophenyl.
14. A method for preparing regorafenib, the regorafenib being represented by formula (I): (I), or a salt thereof, comprising: vi) conjugating a compound of formula (M5) (M5), or a salt thereof, with 6-methoxy-3-amine to form a compound of formula (M6): (M6), or a salt thereof; vii) hydrogenating the compound of formula (M6) or the salt thereof with a hydrogen source to provide a compound of formula (M7): (M7), or a salt thereof; a) conjugating the compound of formula (M7) or the salt thereof with a carbonylating agent in a solvent to form a compound of formula (M8): (M8), or a salt thereof; and b) converting the compound of formula (M8) or the salt thereof into regorafenib of formula (I), or a salt thereof. In step a), the carbonylating agent is carbonyl diimidazole (CDI) or disuccinimidyl carbonate; and X is imidazole group or O-succinimidyl group, or in step a), the carbonylating agent is a chloroformate selected from the group consisting of CH3OC(O)Cl, CH3CH2OC(O)Cl, phenyl-OC(O)Cl, or 4-nitrophenyl-OC(O)Cl; and X is OCH3, OCH2CH3, O-phenyl, or O-4-nitrophenyl.
15. The method of claim 14, prior to step vi), further comprises steps i-1) to vii-1): i-1) combining a compound of formula (SM1): (SM1), or a salt thereof, with a combination of compound SM2 C1-4 alkyl-C(O)Cl or a carbonylating agent with compound SM2 hydroxyamine or oxime to form a compound of formula (M1'): (M1'), or a salt thereof; ii-1) combining a compound of formula (M1') or a salt thereof with 2,6-difluorobenzyl bromide or 2,6-difluorobenzyl chloride to form a compound of formula (M2'): (M2'), or a salt thereof; iii-1) brominating a compound of formula (M2') or a salt thereof with a brominating agent to form a compound of formula (M3'): (M3'), or a salt thereof; iv-1) combining a compound of formula (M3') or a salt thereof with dimethylamine or a salt thereof to provide a compound of formula (M4'): (M4'), or a salt thereof; v-1) Hydrolyzing a compound or salt of formula (M4') with a base to provide a compound or salt of formula (M5): (M5), wherein: The hydroxyamine is represented by HO-NR1R2; the oxime is represented by HO-N=CR3R4; in any of formulas M1' to M4', R is C1-4 alkyl, O-NR1R2, or ON=CR3R4; R1 and R2 are independently hydrogen, tert-butyloxycarbonyl (Boc), C1-4 alkyl, or phenyl; and R3 and R4 are independently hydrogen, C1-4 alkyl, or phenyl.
16. As in request item 15, wherein, In step i-1), the compound SM2 is a hydroxyamine or oxime; and the carbonylating agent is carbonyl diimidazole (CDI), disuccinimide carbonate, CH3OC(O)Cl, CH3CH2OC(O)Cl, phenyl-OC(O)Cl, or 4-nitrophenyl-OC(O)Cl.
17. As in request item 15, wherein, In step i-1), the compound SM2 is acetyl chloride, the hydroxylamine is N-Boc-N-methylhydroxylamine, or the oxime is diphenyl ketoxime.
18. As in request item 15, wherein: In step iii-1), the brominating agent is N-bromosuccinimide; and in step v-1), the base is sodium hydroxide.
19. As in request item 15, wherein, In step i-1), the compound SM is a C1-4 alkyl-C(O)Cl; and any of the compounds of formula (M1') to (M4') are represented by any of the compounds of formula (M1'-1) to (M4'-1): (M1'-1), (M1'-1), (M3'-1), and (M4'-1), or salts thereof.
20. The method of claim 19, wherein the compound SM is acetyl chloride, and any of the compounds of formula (M1'-1) to (M4'-1) are represented by compounds of formula (M1'-1a) to (M4'-1a): (M1'-1a), (M2'-1a), (M3'-1a), and (M4'-1a), or salts thereof.
21. As in request item 15, wherein, In step i-1), the compound SM2 is a hydroxyamine or oxime; and any of the compounds of formula (M1') to (M4') are represented by any of the compounds of formula (M1'-2) to (M4'-2) and (M1'-3) to (M4'-4): (M1'-2), (M2'-2), (M3'-2), (M4'-2), (M1'-3), (M2'-3), (M3'-3), (M4'-3), or salts thereof, wherein R1 and R2 are independently hydrogen, tert-butyloxycarbonyl (Boc), C1-4 alkyl, or phenyl; and R3 and R4 are independently hydrogen, C1-4 alkyl, or phenyl.
22. As in request item 21, wherein, In step i-1), the hydroxylamine is N-Boc-N-methylhydroxylamine; and any of the compounds of formula (M1'-2) to (M4'-2) are represented by compounds of formula (M1'-2a) to (M4'-2a): (M1'-2a), (M2'-2a), (M3'-2a), and (M4'-2a), or salts thereof.
23. As in request item 21, wherein, In step i-1), the oxime is a diphenyl ketoxime; and any of the compounds of formula (M1'-3) to (M4'-3) are represented by compounds of formula (M1'-3a) to (M4'-3a): (M1'-3a), (M2'-3a), (M3'-3a), and (M4'-3a), or salts thereof.
24. A compound selected from the group consisting of (M1'), (M2'), (M3'), and (M4'), and their salts, wherein: R is a C1-4 alkyl, O-NR1R2, or ON=CR3R4; R1 and R2 are independently hydrogen, tert-butyloxycarbonyl (Boc), C1-4 alkyl, or phenyl; and R3 and R4 are independently hydrogen, C1-4 alkyl, or phenyl.
25. The compound of claim 24, wherein the compound is selected from the group consisting of: (M1'-1a), (M2'-1a), (M3'-1a), (M4'-1a), (M1'-2a), (M2'-2a), (M3'-2a), and (M4'-2a), (M1'-3a), (M2'-3a), (M3'-3a), and (M4'-3a), or salts thereof.
Citation Information
Patent Citations
Relugolix synthesis method
CN110194776A
Rerugolix intermediate impurity and preparation method thereof
CN114380810A
Production method of thienopyrimidine derivative
WO2014051164A2
